ImmunityBio announces common stock offering, no amount given

ImmunityBio (IBRX) announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. ImmunityBio currently intends to use the net proceeds from this offering to progress its continued commercialization of ANKTIVA for treatment of BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, to fund its trials in BCG-naive NMIBC and non-small cell lung cancer, toward further research and development, for working capital needs, and for other general corporate purposes. All of the shares are being offered by ImmunityBio. Jefferies and Piper Sandler are acting as joint book-running managers and representatives of the underwriters for the offering. BTIG and H.C. Wainwright & Co. are acting as co-lead managers for the offering.